Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines

Chembiochem. 2022 Jul 5;23(13):e202200183. doi: 10.1002/cbic.202200183. Epub 2022 May 18.

Abstract

Psilocybin (1) is the major alkaloid found in psychedelic mushrooms and acts as a prodrug to psilocin (2, 4-hydroxy-N,N-dimethyltryptamine), a potent psychedelic that exerts remarkable alteration of human consciousness. In contrast, the positional isomer bufotenin (7, 5-hydroxy-N,N-dimethyltryptamine) differs significantly in its reported pharmacology. A series of experiments was designed to explore chemical differences between 2 and 7 and specifically to test the hypothesis that the C-4 hydroxy group of 2 significantly influences the observed physical and chemical properties through pseudo-ring formation via an intramolecular hydrogen bond (IMHB). NMR spectroscopy, accompanied by quantum chemical calculations, was employed to compare hydrogen bond behavior in 4- and 5-hydroxylated tryptamines. The results provide evidence for a pseudo-ring in 2 and that sidechain/hydroxyl interactions in 4-hydroxytryptamines influence their oxidation kinetics. We conclude that the propensity to form IMHBs leads to a higher number of uncharged species that easily cross the blood-brain barrier, compared to 7 and other 5-hydroxytryptamines, which cannot form IMHBs. Our work helps understand a fundamental aspect of the pharmacology of 2 and should support efforts to introduce it (via the prodrug 1) as an urgently needed therapeutic against major depressive disorder.

Keywords: bufotenin; hydrogen bonds; pharmacology; psilocybin; tryptamine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Depressive Disorder, Major*
  • Hallucinogens* / pharmacology
  • Humans
  • Prodrugs*
  • Psilocybin / analogs & derivatives
  • Tryptamines

Substances

  • Hallucinogens
  • Prodrugs
  • Tryptamines
  • Psilocybin
  • psilocin